Status:
COMPLETED
A Comparative Study Between Foraseq and Formoterol/Budesonide Inhalation Capsules in Patients with Asthma
Lead Sponsor:
Eurofarma Laboratorios S.A.
Conditions:
ASTHMA
Eligibility:
All Genders
12+ years
Phase:
PHASE3
Brief Summary
This study primary objective is to compare the impact of two products containing budesonide and formoterol as individual capsules with inhalation powder for the pulmonary function of subjects with per...
Detailed Description
This study primary objective is to compare the impact of two products containing budesonide and formoterol as individual capsules with inhalation powder for the pulmonary function of subjects with per...
Eligibility Criteria
Inclusion
- Sign ICF (see Attachment A);
- Age ≥12 years old
- Diagnosis of mild to moderate persistent asthma, as per the ARIA classification, 35 with symptoms for at least 6 months, clinically stable for at least 1 month with ACQ-7 test34 (see Attachment D) \< 3.0;
- Current use of inhaled corticosteroids (equivalent to beclometasone dipropionate 1000µg) associated or not to long-acting β2-adrenergics and relief medication (salbutamol or equivalent);
- Initial FEV1 of at least 50% of the normal value estimated.
- Serum cortisol evaluation within the normal values
Exclusion
- Use of oral or parenteral corticosteroids within the last 3 months;
- Need of hospitalization due to asthma within the last 3 months;
- Active tabagism, defined as the use of cigarettes, pipe, cigar or any other type in any amount within the last 3 months;
- Severe co-morbidity, such as cardiovascular, renal, liver, neurologic, neoplastic, blood, infectious, dermatologic, neurologic, psychiatric or chronic respiratory diseases, other than asthma;
- Recent participation (\<6 months) or planned participation, during this study, on other clinical trials involving drugs of any nature or under studies of any type of intervention for the asthma treatment;
- Intolerance or allergy to any of the compounds of the drugs evaluated on the study;
- Pregnancy or lactation;
- Chronic use of routine oral or intravenous β-blocker drugs, even ophthalmic solutions.
Key Trial Info
Start Date :
February 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2011
Estimated Enrollment :
88 Patients enrolled
Trial Details
Trial ID
NCT01001364
Start Date
February 1 2010
End Date
April 1 2011
Last Update
March 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centro de Pesquisa Clínica Stelmach
São Paulo, São Paulo, Brazil, 05437 010